Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Leap Therapeutics Inc (LPTX)

Leap Therapeutics Inc (LPTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,033
  • Shares Outstanding, K 88,318
  • Annual Sales, $ 1,500 K
  • Annual Income, $ -40,590 K
  • 60-Month Beta 0.71
  • Price/Sales 70.65
  • Price/Cash Flow N/A
  • Price/Book 1.08
Trade LPTX with:

Options Overview Details

View History
  • Implied Volatility 251.52% ( +88.63%)
  • Historical Volatility 131.24%
  • IV Percentile 98%
  • IV Rank 94.38%
  • IV High 261.99% on 03/11/22
  • IV Low 75.54% on 11/17/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,035
  • Volume Avg (30-Day) 202
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 15,734
  • Open Int (30-Day) 16,088

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9200 +20.65%
on 05/12/22
1.4400 -22.92%
on 04/28/22
-0.2800 (-20.14%)
since 04/27/22
3-Month
0.9200 +20.65%
on 05/12/22
2.1199 -47.64%
on 02/28/22
-0.8900 (-44.50%)
since 02/25/22
52-Week
0.9200 +20.65%
on 05/12/22
4.1700 -73.38%
on 09/30/21
-0.5100 (-31.48%)
since 05/27/21

Most Recent Stories

More News
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe

Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive. However, sole dependence on Oxbryta for growth is a concern.

RHHBY : 43.0600 (-0.62%)
GBT : 26.15 (+2.71%)
AGLE : 1.5700 (+1.29%)
LPTX : 1.1100 (-7.50%)
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

BIIB : 206.20 (+0.97%)
AGLE : 1.5700 (+1.29%)
LPTX : 1.1100 (-7.50%)
INMB : 6.80 (+7.42%)
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

REGN : 692.80 (+1.37%)
ABBV : 150.00 (-0.38%)
LPTX : 1.1100 (-7.50%)
SWTX : 18.36 (-40.45%)
Seagen (SGEN) Posts Positive Data from New Study on Tukysa

Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.

RHHBY : 43.0600 (-0.62%)
MRK : 93.08 (+0.83%)
SGEN : 141.39 (+2.12%)
LPTX : 1.1100 (-7.50%)
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.

ABBV : 150.00 (-0.38%)
AGLE : 1.5700 (+1.29%)
LPTX : 1.1100 (-7.50%)
EYPT : 9.69 (+7.19%)
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata

The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.

LLY : 323.48 (+3.20%)
INCY : 77.19 (+1.54%)
AGLE : 1.5700 (+1.29%)
LPTX : 1.1100 (-7.50%)
Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

PGEN : 1.3800 (+3.76%)
LPTX : 1.1100 (-7.50%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies...

BHVN : 143.37 (+0.13%)
LPTX : 1.1100 (-7.50%)
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
LPTX : 1.1100 (-7.50%)
GMDA : 2.22 (+2.78%)
ALXO : 8.05 (+1.39%)
MRK : 93.08 (+0.83%)
Why Leap Therapeutics Stock Is Surging Today

Positive clinical trial results are giving investors a reason to cheer.

LPTX : 1.1100 (-7.50%)
BGNE : 133.96 (+2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 1.4415
2nd Resistance Point 1.3104
1st Resistance Point 1.2102
Last Price 1.1100
1st Support Level 0.9789
2nd Support Level 0.8478
3rd Support Level 0.7476

See More

52-Week High 4.1700
Fibonacci 61.8% 2.9285
Fibonacci 50% 2.5450
Fibonacci 38.2% 2.1615
Last Price 1.1100
52-Week Low 0.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar